Palvella Therapeutics Inc (PVLA) financials
Palvella Therapeutics revenue and earnings by year
Palvella Therapeutics's revenue was $25.9 million in the fiscal year to December 31, 2022, down 17.6% from the year before. Net income was -$33.3 million, -128.5% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 28.2% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 7 fiscal years
| Fiscal year to | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 26 | 31 | 29 | 46 | 29 | 25 | 6 |
| Revenue growth | -17.6% | 7.1% | -36.6% | 59.0% | 15.1% | 333.5% | — |
| Operating income | -43 | -52 | -34 | -27 | -31 | -15 | -23 |
| Operating margin | -167.8% | -165.0% | -115.7% | -58.7% | -105.9% | -57.7% | -390.3% |
| Net income | -33 | -46 | -37 | -25 | -27 | -18 | -23 |
| Net margin | -128.5% | -145.6% | -127.0% | -55.0% | -91.9% | -69.8% | -391.0% |
| Diluted EPS | -$36.00 | -$56.80 | -$54.00 | -$44.00 | -$39.20 | -$32.00 | -$43.20 |
| Free cash flow | -61 | -9 | -49 | -55 | -3 | 48 | -15 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open PVLA in Markets.
See also: PVLA returns
No forecast, no recommendation. This page describes Palvella Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.